Department of Pathology and Laboratory Medicine, Temple University School of Medicine, 3401 N. Broad St., Philadelphia, PA 19140, USA.
J Neuroimmune Pharmacol. 2013 Jun;8(3):608-20. doi: 10.1007/s11481-013-9445-9. Epub 2013 Mar 8.
An accumulating body of evidence suggests that endocannabinoids and cannabinoid receptors type 1 and 2 (CB(1), CB(2)) play a significant role in physiologic and pathologic processes, including cognitive and immune functions. While the addictive properties of marijuana, an extract from the Cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, HIV-1 infection, stroke, Alzheimer's disease to name a few), mainly mediated by CB(2) activation. Development of CB(2) agonists as therapeutic agents has been hampered by the complexity of their intracellular signaling, relative paucity of highly selective compounds and insufficient data regarding end effects in the target cells and organs. This review attempts to summarize recent advances in studies of CB(2) activation in the setting of neuroinflammation, immunomodulation and HIV-1 infection.
越来越多的证据表明,内源性大麻素和大麻素受体 1 型和 2 型(CB1、CB2)在包括认知和免疫功能在内的生理和病理过程中发挥着重要作用。虽然大麻(大麻植物的提取物)的成瘾性已被广泛认识,但人们越来越认识到大麻素在多种涉及慢性炎症的病理状况中的治疗潜力(炎症性肠病、关节炎、自身免疫性疾病、多发性硬化症、HIV-1 感染、中风、阿尔茨海默病等),主要通过 CB2 激活介导。由于其细胞内信号转导的复杂性、相对缺乏高选择性化合物以及关于靶细胞和器官的终末效应的数据不足,CB2 激动剂作为治疗剂的开发受到了阻碍。本文综述了近年来在神经炎症、免疫调节和 HIV-1 感染背景下 CB2 激活研究方面的进展。